As­traZeneca picks win­ner in in­haled JAK 'bake-of­f' while sweep­ing Alex­ion drug out

As­traZeneca is push­ing an Alex­ion lega­cy drug out of the pipeline as part of the rou­tine quar­ter­ly house-clean­ing ex­er­cise.

ALXN1830, an FcRn block­er that Alex­ion had scored in its $1.2 bil­lion buy­out of Syn­tim­mune back in 2018, has been re­moved from Phase I. It had been test­ed as a treat­ment for warm au­toim­mune he­molyt­ic ane­mia.

Marc Dunoy­er, Alex­ion CEO, said the de­ci­sion was “due to rea­sons which are in our view spe­cif­ic to the mol­e­cule.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER